Treatment of osteoporosis with vitamin D.
Kanis
J A
JA
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK.
McCloskey
E V
EV
de Takats
D
D
Bernard
J
J
Zhang
D M
DM
D015519:Bone Density / Q000187:drug effects; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002762:Cholecalciferol / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004872:Ergocalciferols / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006934:Hypercalcemia / Q000139:chemically induced; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D016103:Spinal Fractures / Q000517:prevention & control; D014807:Vitamin D / Q000627:therapeutic use*
D004872:Ergocalciferols; D006887:Hydroxycholecalciferols; D014807:Vitamin D; D002762:Cholecalciferol; D002117:Calcitriol; C008088:alfacalcidol